Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

GSK’s RSV vaccine Arexvy, Bayer’s Astepro and Haleon’s Tums. Of note, Tums had the lowest estimated national TV ad spend during the month with $2.7 million. Brands that fell off the list from July’s ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that they have entered into a ...

Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision ...

And Arexvy was the focus of another winner ... tool launched earlier this year to support the Allegra allergy relief brand. When planning a walk or bike ride, consumers can use Allegra Airways ...

"Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I" was originally created and published by ...

The FDA in June expanded the use of GSK's Arexvy vaccine in adults between the ... dragged down by Mercedes brand, Asia 8:15 AM UTC · Updated ago European Marketscategory German exports rise ...

Moderna’s RSV vaccine, approved for adults 60 and over, also faces competition from GSK’s Arexvy, which holds a ... because we believe its strong brand, valuable IP, and expanding streaming ...